No significant difference in SRE risk on the basis of intravenous bisphosphonate dosing was observed for patients with newly diagnosed multiple myeloma. Credit: Getty Images. Fewer administrations of ...

Zoledronic acid has several advantages over other bisphosphonates. In addition to having broader clinical utility, zoledronic acid can safely be infused over 15 minutes rather than the 2 hours ...

Development of an Actionable Framework to Address Cancer Care Disparities in Medically Underserved Populations in the United States: Expert Roundtable Recommendations We conducted a retrospective ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

Patients treated with intravenous bisphosphonates are at an increased risk of jaw or facial bone deterioration or infection, according to a study published online June 26 in the Journal of the ...

Add Yahoo as a preferred source to see more of our stories on Google. If you’re one of the 8 million American women with osteoporosis, your doctor has probably talked to you about treatment options to ...

Hypercalcemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer, and is associated with a high degree of morbidity and mortality. It affects an estimated 2%–30 ...

Cancer patients taking bisphosphonate drugs for the prevention of fractures appear more likely to develop jaw disease than patients who do not take the drugs, according to an analysis of records from ...

Mortality risk did not differ significantly after AFF vs after hip or ST/FS fractures among men receiving bisphosphonates for fracture prevention.

NEW YORK (Reuters Health) Jan. 3 A report in the Journal of the American Dental Association for January clarifies the risk of jaw osteonecrosis associated with bisphosphonates. Intravenous ...